Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of amygdalin in preparing knee osteoarthritis anti-inflammatory drug

A technology for knee osteoarthritis and anti-inflammatory drugs is applied in the application field of amygdalin in the preparation of chondrocyte anti-inflammatory drugs to achieve the effects of controlling side effects, enhancing anti-inflammatory ability and delaying degeneration

Active Publication Date: 2018-12-21
浙江中医药大学附属第一医院
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the specific mechanism of how traditional Chinese medicine for tonifying kidney and activating blood regulates MMPs and ADAMTS5 in an inflammatory environment needs further study.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of amygdalin in preparing knee osteoarthritis anti-inflammatory drug
  • Application of amygdalin in preparing knee osteoarthritis anti-inflammatory drug
  • Application of amygdalin in preparing knee osteoarthritis anti-inflammatory drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Expression characteristics of DNMT3B in human osteoarthritis cartilage

[0035] 1. Comparing the expression of DNMT3B in articular cartilage of non-diseased healthy people and OA patients

[0036] 1.1 Experimental samples: Normal articular cartilage tissue was collected from amputated patients' articular cartilage tissue (11 cases of talus or knee joint), and knee cartilage tissue of OA patients was collected from degenerated knee articular cartilage tissue under surgical replacement after total knee arthroplasty ( 57 cases).

[0037] 1.2 Experimental grouping

[0038] (A) Non-disease (ND) group; (B) OA group.

[0039] 1.3 Acquisition of articular cartilage tissue and preparation of slices

[0040] After the samples of each group were washed several times with HBSS (Hank's Balanced Salt Solution), they were soaked in 10% NBF (prepared with ultrapure water) for 3 days to fully fix them. After fixation, rinse with deionized water 6 times (15 minutes / time), t...

Embodiment 2

[0116] Example 2 In vitro study of amygdalin delaying chondrocyte degeneration by regulating Dnmt3b

[0117] 1. Method

[0118] 1. Screening of optimal drug concentration for AMD in chondrocytes

[0119] 1.1 Experimental grouping

[0120] (A) blank group; (B) control group; (C) drug group.

[0121] 1.2 Isolation and culture of mouse articular chondrocytes

[0122] 1) Take 2-week-old C57BL / 6J mice and use CO 2 After sacrifice, soak them in 70% alcohol for 5-10 minutes.

[0123] 2) Take out the mouse, peel off the skin, grab the cartilage layer of the femoral head with tweezers, cut off the attached ligament and soft tissue with scissors, and place the cartilage tissue in a 1.5 mL centrifuge tube containing DPBS.

[0124] 3) Remove the absorbent cloth, clean the ultra-clean workbench, change gloves, and preheat the digestion medium (DMEM medium + 10% FBS + 1% P / S + collagenase P 0.5 mg / mL) at 37°C.

[0125] 4) Wash the cartilage cap in the 1.5mL centrifuge tube with DPBS 4...

Embodiment 3

[0169] Example 3 In vitro study of amygdalin preventing chondrocyte degeneration by regulating p38 / MAPK / Dnmt3b signaling pathway

[0170] Objective To clarify the changes of inflammation-related pathways in chondrocytes regulated by AMD in the inflammatory state, and to clarify the mechanism of AMD preventing chondrocyte degeneration.

[0171] 1. Method

[0172] 1. To clarify the regulatory effect of AMD on inflammation-related pathways in chondrocytes in the inflammatory state

[0173] 1.1 Experimental grouping

[0174] (A) Veh group; (B) IL-1β group; (C) AMD group; (D) IL-1β+AMD group.

[0175] 1.2 Isolation and culture of mouse articular chondrocytes

[0176] Articular chondrocytes were isolated from knee joints of 2-week-old C57BL / 6J mice. Separation method method is the same as embodiment 2 experimental method 2.2. Take 2.5×10 5 / mL density was inoculated into tissue culture plates containing basal medium (DMEM medium+10%FBS+1%P / S).

[0177] 1.3 Inflammatory factor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of amygdalin in preparing a knee osteoarthritis anti-inflammatory drug. At an inflammatory state, AMD controls the expression of Dnmt3b by inhibiting a p38 / MAPK signal channel so as to retard the regression of cartilage cells. The AMD adjusts the metabolism of the cartilage cells by controlling the p38 / MAPK / Dnmt3b signal channel, so that the regression of OA isretarded. Therefore, AMD has good application prospect in clinically treating osteoarthritis. The existing anti-inflammatory pain alleviating drug generally has gastrointestinal reaction, anaphylacticreaction, renal damage and the like, the amygdalin can well control the side effect in an effective dose range and does not influence the improvement of the anti-inflammatory capability of cartilagecells.

Description

technical field [0001] The invention relates to a new application of amygdalin, that is, the application of amygdalin in the preparation of medicine for treating knee osteoarthritis, especially the application of amygdalin in the preparation of chondrocyte anti-inflammatory medicine. Background technique [0002] Arthritis is the most common cause of motor system disability, and osteoarthritis (OA) is the most common type of arthritis. As a degenerative joint disease, OA is characterized by the degeneration of articular cartilage, subchondral bone sclerosis, inflammation and the formation of osteophytes. Its clinical symptoms mainly include chronic pain, joint instability, stiffness, and radiographic joint space narrowing. The pathogenic factors of OA are diverse, including obesity, joint deformity, occupational flexion and weight bearing, history of joint surgery and trauma, and genetic factors. At present, it is believed that the degeneration of articular cartilage is th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7028A61P29/00A61P19/02
CPCA61K31/7028A61P19/02A61P29/00
Inventor 金红婷徐涛涛王萍儿应俊金星沈杰童培建吴承亮肖鲁伟
Owner 浙江中医药大学附属第一医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com